Science News
from research organizations

Living with the risk of Alzheimer's disease

Date:
September 1, 2016
Source:
University of Cologne - Universität zu Köln
Summary:
What are the expectations of persons who decide to have their risk of Alzheimer’s Disease tested? What should doctors pay attention to when ascertaining individual risks? What is the benefit of risk determination for patients and their close others, while options to treat the disease remain insufficient? According to current estimates, the number of individuals suffering from Alzheimer’s Disease worldwide is 40 million – and rising. The burdens imposed on the patients, on their caregivers, and on society are considerable.
Share:
FULL STORY

What are the expectations of persons who decide to have their risk of Alzheimer's Disease tested? What should doctors pay attention to when ascertaining individual risks? What is the benefit of risk determination for patients and their close others, while options to treat the disease remain insufficient?

According to current estimates, the number of individuals suffering from Alzheimer's Disease worldwide is 40 million -- and rising. The burdens imposed on the patients, on their caregivers, and on society are considerable.

Due to recent advances in the prediction of Alzheimer's Disease, examinations for risk assessment are rapidly increasing -- often by the patients' own demand. This prediction may, however, have a major psychological impact on patients and their close others, since there is no effective treatment to prevent Alzheimer's Disease.

The interdisciplinary project "Ethical and Legal Framework for Predictive Diagnosis of Alzheimer's Disease: Quality of Life of Individuals at Risk and Their Close Others (PreDADQoL)" addresses these issues and aims to close an important research gap by providing an ethical and legal framework for the predictive testing of Alzheimer's Disease. The project will be conducted under the auspices of the Center for Ethics, Rights, Economics and Social Sciences of Health (ceres) at the University of Cologne in cooperation with the Fundació ACE Barcelona, one of the largest Alzheimer's clinics in Europe.

PreDADQoL will be funded by the Federal Ministry of Education and Research for three years with an amount of 300,000 €. The coordinating supervisor is the executive director of ceres, Prof. Christiane Woopen. The research team consists of the executive director of the Institute for Medical Law of the University of Cologne, Prof. Christian Katzenmeier, the director of the Department of Psychiatry and Psychotherapy at the University Hospital Cologne, Prof. Frank Jessen, and the director of the Barcelona Alzheimer Treatment & Research Center, Mercè Boada, MD, PhD.

ceres, the Cologne Center for Ethics, Rights, Economics and Social Sciences of Health, is a cross-departmental center for interdisciplinary research, education and advanced training in the area of health. ceres also carries out advisory functions on health-related matters. The center was founded by five Faculties and the President of the University of Cologne.


Story Source:

Materials provided by University of Cologne - Universität zu Köln. Note: Content may be edited for style and length.


Cite This Page:

University of Cologne - Universität zu Köln. "Living with the risk of Alzheimer's disease." ScienceDaily. ScienceDaily, 1 September 2016. <www.sciencedaily.com/releases/2016/09/160901093004.htm>.
University of Cologne - Universität zu Köln. (2016, September 1). Living with the risk of Alzheimer's disease. ScienceDaily. Retrieved May 8, 2017 from www.sciencedaily.com/releases/2016/09/160901093004.htm
University of Cologne - Universität zu Köln. "Living with the risk of Alzheimer's disease." ScienceDaily. www.sciencedaily.com/releases/2016/09/160901093004.htm (accessed May 8, 2017).